Clinical Diagnosis

The Eye Care Network connected with Haller to hear her vision for Wills Eye Hospital, her priorities as CEO, and what lies ahead for the field of ophthalmology.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and patient experience.

Changing demographics and increasing trial complexity present challenges and opportunities.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance on glasses and contacts.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options

At ARVO 2025, in Salt Lake City, Utah, Danielle Gauthier talked about her poster on autosomal dominant Alzheimer disease in relation to optic nerve head drusen.

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on Ophthalmic Innovation is reshaping the field, streamlining outdated processes, and advancing patient-centered solutions worldwide.

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.

CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience